Тилавонемаб

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

2096513-89-0

immunoglobulin G4-kappa, anti-[Homo sapiens MAPT (microtubuleassociated protein tau, tau)], monoclonal antibody;
gamma4 heavy chain (1-442) [VH (Mus musculus IGHV6-3*01 (91.9%) - (IGHD) -IGHJ4*01 (92.3%)/Homo sapiens IGHV3-7*01 (71.4%) -(IGHD) - IGHJ4*01 (92.3%)) [8.10.6] (1-115) -Homo sapiens IGHG4*01 (CH1 (116- 213), hinge S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (115-442)], (129-218')-disulfide with kappa light chain (1'-218') [V-KAPPA (Mus musculus IGKV3-7*01 (90.9%) -IGKJ2*03 (90.9%)/Homo sapiens IGKV4-1*01 (69.3%) -IGKJ2*01 (100%)) [10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (221-221'':224-224'')-bisdisulfide

Поделиться этой страницей